Regulus Therapeutics Inc., of Carlsbad, Calif., received a patent within the Esau patent estate covering methods of inhibiting miR-122, a liver-specific microRNA that has been shown to facilitate replication of hepatitis C virus infection.
RXi Pharmaceuticals Corp., of Worcester, Mass., received a notice of allowance on patent applications filed by Thermo Fisher Scientific Inc., of Waltham, Mass., which encompass siRNA sequences targeting superoxide kinase 4, hepatocyte growth factor receptor and cyclin-dependent kinase inhibitor p27.
Salix Pharmaceuticals Ltd., of Raleigh, N.C., was issued U.S. Patent No. 7,612,199, titled "Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin." It provides further protection relating to composition of matter relating to physical chemical states of rifaximin.
Stem Cell Therapy International Inc., of Tampa, Fla., said subsidiary Histostem Ltd., of South Korea, was granted U.S. Patent No. 7,582,477 B2, titled "Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood."
The Medicines Co., of Parsippany, N.J., was issued U.S. Patent No. 7,598,343, relating to a more consistent and improved Angiomax drug product made by processes described in the patent.
Vivaldi Biosciences Inc., of New York, received U.S. Patent No. 7,588,768, which covers a live attenuated influenza vaccines with modifications to the viral NS1 gene and methods for producing the vaccines in cell culture systems.